Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23846
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHolden, N. J.en
dc.contributor.authorWilliams, J. M.en
dc.contributor.authorMorgan, M. D.en
dc.contributor.authorChalla, A.en
dc.contributor.authorGordon, J.en
dc.contributor.authorPepper, R. J.en
dc.contributor.authorSalama, A. D.en
dc.contributor.authorHarper, L.en
dc.contributor.authorSavage, C. O.en
dc.date.accessioned2015-11-24T19:36:17Z-
dc.date.available2015-11-24T19:36:17Z-
dc.identifier.issn1468-2060-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23846-
dc.rightsDefault Licence-
dc.subjectAntibodies, Antineutrophil Cytoplasmic/*immunologyen
dc.subjectAntibodies, Monoclonal, Murine-Derived/therapeutic useen
dc.subjectB-Cell Activating Factor/*blooden
dc.subjectB-Lymphocytes/*immunologyen
dc.subjectCell Survival/immunologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectImmunoglobulin G/blooden
dc.subjectImmunologic Factors/therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectNeutrophils/*immunologyen
dc.subjectSystemic Vasculitis/drug therapy/immunologyen
dc.subjectTumor Cells, Cultureden
dc.subjectTumor Necrosis Factor-alpha/immunologyen
dc.titleANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular processen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1136/ard.2011.153890-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21859691-
heal.identifier.secondaryhttp://ard.bmj.com/content/70/12/2229-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2011-
heal.abstractOBJECTIVES: To determine a role for antineutrophil cytoplasmic antibody (ANCA)-activated neutrophils in promoting B cell survival through the release of B lymphocyte stimulator (BLyS). METHODS: Neutrophil BLyS expression was measured by flow cytometry. Concentrations of BLyS in cell supernatants and donor serum samples were measured by ELISA. Cell survival assays were carried out using an L3055 cell line and viability measured by flow cytometry. RESULTS: Tumour necrosis factor alpha and formyl-Met-Leu-Phe (fMLP) treatment of non-primed neutrophils and treatment of primed neutrophils with anti-PR3 ANCA IgG resulted in a significant increase in surface expression of BLyS within 30 min which returned to basal levels by 2 h. Supernatants from ANCA-stimulated neutrophils were shown to contain increased levels of BLyS and to promote the survival of the centroblast cell line L3055. Serum BLyS concentrations are increased in patients with active ANCA-associated systemic vasculitis and these levels are increased further following 1-3 months of treatment with rituximab. CONCLUSIONS: ANCA specifically causes the release of BLyS from activated neutrophils which can support B cell survival in vitro. The presence of serum BLyS in active disease and its increase following B cell depletion suggest it is an important factor in disease pathogenesis and may facilitate disease relapse.en
heal.journalNameAnn Rheum Disen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons